

Author and Reference	Year of publication	Number of patients	Previous (failed) treatments	Duration (days)	Eradication (%)
<i>Gatta et al. [275]</i>	2005	151	1 st : PPI+C+A or M 2 nd : PPI+C+A or M;	7-14	76
<i>Gisbert et al [276]</i>	2006	100	1 st : PPI+C+A 2 nd : Q	10	60
<i>Gisbert et al [277]</i>	2006	20	1 st : PPI+C+A 2 nd : Q	10	85
<i>Hsu et al [262]</i>	2008	37	1 st : PPI+C+A 2 nd : Q	10	84
<i>Rokkas et al [278]</i>	2009	30	1 st : PPI+C+A 2 nd : Q	10	70
<i>Gisbert et al [279]</i>	2012	200	1 st : PPI+C+A 2 nd : Q	10	68
<i>Burgos-Santamaría [280]</i>	2019	65	1 st : PPI+C+A 2 nd : Q	7-14	75
<i>Burgos-Santamaría [280]</i>	2019	19	1 st : PPI+C+A 2 nd : Q	14	84
<i>Burgos-Santamaría [281]</i>	2021	39	1 st : PPI+C+A±M 2 nd : Q	10-14	74
<i>Burgos-Santamaría [281]</i>	2021	28	1 st : PPI+C+A±M 2 nd : Q	14	75

PPI: proton pump inhibitor; C: clarithromycin; M: metronidazole; A: amoxicillin; Q: bismuth-containing quadruple therapy (PPI, bismuth, tetracycline and M).

[†]Bismuth was added to the triple regimen with a proton pump inhibitor, amoxicillin, and levofloxacin.